Tofacitinib: Real-World Data and Treatment Persistence in Rheumatoid Arthritis

Ilaria Bertoldi,1 Roberto Caporali2 1Medical Department, Pfizer Italy, Rome, Italy; 2Department of Clinical Sciences and Community Health, University of Milan and ASST Pini-CTO Hospital, Milan, ItalyCorrespondence: Roberto CaporaliDepartment of Clinical Sciences and Community Health, University of M...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Bertoldi I, Caporali R
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	rheumatoid arthritis real-world effectiveness persistence Diseases of the musculoskeletal system RC925-935
Acceso en línea:	https://doaj.org/article/bbee0d24648e4d5e8c2c40c9178099af
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:bbee0d24648e4d5e8c2c40c9178099af
record_format	dspace
spelling	oai:doaj.org-article:bbee0d24648e4d5e8c2c40c9178099af2021-12-02T18:07:05ZTofacitinib: Real-World Data and Treatment Persistence in Rheumatoid Arthritis1179-156Xhttps://doaj.org/article/bbee0d24648e4d5e8c2c40c9178099af2021-07-01T00:00:00Zhttps://www.dovepress.com/tofacitinib-real-world-data-and-treatment-persistence-in-rheumatoid-ar-peer-reviewed-fulltext-article-OARRRhttps://doaj.org/toc/1179-156XIlaria Bertoldi,1 Roberto Caporali2 1Medical Department, Pfizer Italy, Rome, Italy; 2Department of Clinical Sciences and Community Health, University of Milan and ASST Pini-CTO Hospital, Milan, ItalyCorrespondence: Roberto CaporaliDepartment of Clinical Sciences and Community Health, University of Milan and ASST Pini-CTO Hospital, Milan, ItalyEmail roberto.caporali@unimi.itAbstract: Tofacitinib is an oral Janus kinase (JAK) inhibitor indicated for the treatment of rheumatoid arthritis (RA). The efficacy and safety/tolerability of tofacitinib have been extensively evaluated as monotherapy and combination therapy in multiple, randomised, multicentre studies in patients with RA. Tofacitinib as monotherapy (as first- and second-line treatment) or as combination with methotrexate (MTX) or other csDMARDs as second- and third-line treatment is effective and generally well tolerated in patients with RA. This article focuses on recent real-world evidence investigating the effectiveness, treatment persistence and safety/tolerability of tofacitinib in patients with RA. With this purpose, a literature review was conducted from April 2018 up to October 2020 for the effectiveness, persistence and safety of tofacitinib for the treatment of RA, primarily focusing on real-world studies. These retrospective and prospective and observational studies demonstrate the effectiveness of tofacitinib, thus supporting pivotal data from the clinical trial programme. Treatment persistence was generally comparable to that of biologic disease-modifying anti-rheumatic drugs. Safety findings in these observational studies were consistent with the known safety profile of the approved dose of 5 mg twice daily.Keywords: rheumatoid arthritis, real-world, effectiveness, persistenceBertoldi ICaporali RDove Medical Pressarticlerheumatoid arthritisreal-worldeffectivenesspersistenceDiseases of the musculoskeletal systemRC925-935ENOpen Access Rheumatology: Research and Reviews, Vol Volume 13, Pp 221-237 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	rheumatoid arthritis real-world effectiveness persistence Diseases of the musculoskeletal system RC925-935
spellingShingle	rheumatoid arthritis real-world effectiveness persistence Diseases of the musculoskeletal system RC925-935 Bertoldi I Caporali R Tofacitinib: Real-World Data and Treatment Persistence in Rheumatoid Arthritis
description	Ilaria Bertoldi,1 Roberto Caporali2 1Medical Department, Pfizer Italy, Rome, Italy; 2Department of Clinical Sciences and Community Health, University of Milan and ASST Pini-CTO Hospital, Milan, ItalyCorrespondence: Roberto CaporaliDepartment of Clinical Sciences and Community Health, University of Milan and ASST Pini-CTO Hospital, Milan, ItalyEmail roberto.caporali@unimi.itAbstract: Tofacitinib is an oral Janus kinase (JAK) inhibitor indicated for the treatment of rheumatoid arthritis (RA). The efficacy and safety/tolerability of tofacitinib have been extensively evaluated as monotherapy and combination therapy in multiple, randomised, multicentre studies in patients with RA. Tofacitinib as monotherapy (as first- and second-line treatment) or as combination with methotrexate (MTX) or other csDMARDs as second- and third-line treatment is effective and generally well tolerated in patients with RA. This article focuses on recent real-world evidence investigating the effectiveness, treatment persistence and safety/tolerability of tofacitinib in patients with RA. With this purpose, a literature review was conducted from April 2018 up to October 2020 for the effectiveness, persistence and safety of tofacitinib for the treatment of RA, primarily focusing on real-world studies. These retrospective and prospective and observational studies demonstrate the effectiveness of tofacitinib, thus supporting pivotal data from the clinical trial programme. Treatment persistence was generally comparable to that of biologic disease-modifying anti-rheumatic drugs. Safety findings in these observational studies were consistent with the known safety profile of the approved dose of 5 mg twice daily.Keywords: rheumatoid arthritis, real-world, effectiveness, persistence
format	article
author	Bertoldi I Caporali R
author_facet	Bertoldi I Caporali R
author_sort	Bertoldi I
title	Tofacitinib: Real-World Data and Treatment Persistence in Rheumatoid Arthritis
title_short	Tofacitinib: Real-World Data and Treatment Persistence in Rheumatoid Arthritis
title_full	Tofacitinib: Real-World Data and Treatment Persistence in Rheumatoid Arthritis
title_fullStr	Tofacitinib: Real-World Data and Treatment Persistence in Rheumatoid Arthritis
title_full_unstemmed	Tofacitinib: Real-World Data and Treatment Persistence in Rheumatoid Arthritis
title_sort	tofacitinib: real-world data and treatment persistence in rheumatoid arthritis
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/bbee0d24648e4d5e8c2c40c9178099af
work_keys_str_mv	AT bertoldii tofacitinibrealworlddataandtreatmentpersistenceinrheumatoidarthritis AT caporalir tofacitinibrealworlddataandtreatmentpersistenceinrheumatoidarthritis
_version_	1718378652656205824

Tofacitinib: Real-World Data and Treatment Persistence in Rheumatoid Arthritis

Ejemplares similares